Grape King Bio Ltd (TPE:1707)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
130.00
+0.50 (0.39%)
At close: Dec 5, 2025
-17.46%
Market Cap 19.26B
Revenue (ttm) 10.40B
Net Income (ttm) 1.22B
Shares Out 148.14M
EPS (ttm) 8.19
PE Ratio 15.87
Forward PE n/a
Dividend 6.90 (5.33%)
Ex-Dividend Date Jan 8, 2026
Volume 50,699
Average Volume 104,586
Open 129.50
Previous Close 129.50
Day's Range 129.00 - 130.00
52-Week Range 119.50 - 158.00
Beta 0.41
RSI 62.53
Earnings Date Nov 11, 2025

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio... [Read more]

Sector Healthcare
Founded 1969
Employees 501
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1707
Full Company Profile

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.

Financial Statements

News

There is no news available yet.